Accuray Incorporated (NASDAQ:ARAY) Director Joseph E. Whitters bought 12,500 shares of Accuray stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average cost of $2.62 per share, for a total transaction of $32,750.00. Following the completion of the transaction, the director now directly owns 116,780 shares in the company, valued at $305,963.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
ARAY stock opened at $3.11 on Friday. The firm has a fifty day moving average price of $3.23 and a 200 day moving average price of $3.95. Accuray Incorporated has a fifty-two week low of $2.35 and a fifty-two week high of $5.40. The company has a debt-to-equity ratio of 3.21, a quick ratio of 1.16 and a current ratio of 1.79. The firm has a market cap of $269.89 million, a PE ratio of -20.73 and a beta of 1.96.
Accuray (NASDAQ:ARAY) last posted its earnings results on Thursday, August 15th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). Accuray had a negative net margin of 3.92% and a negative return on equity of 26.69%. The company had revenue of $117.42 million during the quarter, compared to analysts’ expectations of $116.09 million. During the same quarter last year, the firm earned ($0.01) EPS. On average, equities analysts predict that Accuray Incorporated will post -0.14 EPS for the current year.
ARAY has been the topic of several research analyst reports. Royal Bank of Canada set a $4.00 target price on shares of Accuray and gave the company a “hold” rating in a research note on Friday, August 16th. BidaskClub upgraded shares of Accuray from a “strong sell” rating to a “sell” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. Accuray currently has an average rating of “Hold” and a consensus target price of $4.47.
Institutional investors and hedge funds have recently modified their holdings of the stock. Heartland Advisors Inc. grew its holdings in Accuray by 0.9% in the 2nd quarter. Heartland Advisors Inc. now owns 3,468,500 shares of the medical equipment provider’s stock valued at $13,423,000 after buying an additional 29,288 shares in the last quarter. D. E. Shaw & Co. Inc. grew its holdings in Accuray by 16.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,755,925 shares of the medical equipment provider’s stock valued at $10,665,000 after buying an additional 384,714 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Accuray by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,321,330 shares of the medical equipment provider’s stock valued at $7,916,000 after buying an additional 78,330 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Accuray by 80.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,269,283 shares of the medical equipment provider’s stock valued at $8,783,000 after buying an additional 1,011,363 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Accuray by 0.8% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 1,199,211 shares of the medical equipment provider’s stock valued at $4,641,000 after buying an additional 9,400 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Read More: How to interpret the current ratio
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.